Statins could prevent arterial ageing, study suggests
29 Sep 2008

Statins could keep the arteries of advanced heart disease patients feeling younger, it has been suggested.

A study carried out by staff at the University of Cambridge in the UK and published in the journal Circulation Research suggests the cholesterol-lowering drugs could hold back the arterial aging process in such people.

The research found statins seem to increase levels of the protein NBS-1, which is related to the repair of DNA within cells, meaning they could hold off the effects of old age in artery walls, the BBC reports.

Professor Martin Bennett, study leader, said: "It's an exciting breakthrough to find that statins not only lower cholesterol but also rev up the cells' own DNA repair kit, slowing the ageing process of the diseased artery."

He suggests if statins can do this for other cells, they could protect normal tissue from DNA damage that occurs as part of cancer treatments such as radiotherapy and chemotherapy, potentially reducing the side effects.

Login and visit the Cholesterol Knowledge Centre

Print Article    Bookmark

• Cholesterol treatment receives US approval 16/12/08
• Study confirms no interference between cholesterol and lymphoma treatments 09/12/08
• New game could help tackle obesity and diabetes in kids, expert claims 04/12/08
• Some "good cholesterol" not good enough, study suggests 02/12/08
• Study links grapes with reduced cardio risk 29/10/08

• ZOCOR (statin) - 51.11%
  ... cholesterol, LDL-cholesterol, apolipoprotein B and triglycerides in primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia when response to diet and other non- pharmacological measures is inadequate. To lower LDL:HDL ratio and total cholesterol ...
  
  
• LIPITOR (statin) - 50.64%
  Adjunct to diet for reduction of elevated total cholesterol, LDL- cholesterol, apolipoprotein B, and triglycerides in patients with primary hypercholesterolaemia, heterozygous and homozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia when response to diet and other non ...
  
  
• Simvastatin (statin) - 50.64%
  As an adjunct to diet for reduction of total cholesterol, LDL-cholesterol, apolipoprotein B and triglycerides in primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia when response to diet and other non- pharmacological measures is inadequate ...
  
  
• LESCOL XL (statin) - 49.42%
  As an adjunct to diet for the reduction of elevated total cholesterol (total-C), low- density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B) and triglycerides (TG) levels and for the increase of high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolaemia ...
  
  
• LIPOSTAT (statin) - 48.68%
  ... procedure in patients with a history of either a myocardial infarction or unstable angina pectoris and a total serum cholesterol level in excess of 4.8mmol/L or a LDL- cholesterol in excess of 3.2mmol/ L. Coronary atherosclerotic disease: adjunct to diet to slow progressve course of coronary ...
  
  
• CHOLESTAGEL Film-Coated Tablets - 47.95%
  ... reduction in LDL-cholesterol (LDL-C) levels in patients with primary hypercholesterolaemia who are not adequately controlled with a statin alone. Cholestagel as monotherapy is indicated as adjunctive therapy to diet for reduction of elevated total and LDL-cholesterol in patients with isolated ...